Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Sciele Pharma Inc. Stories

2009-09-14 06:00:00

SILVER SPRING, Md., Sept. 14 /PRNewswire/ -- The National Association of School Nurses (NASN) announced today the kickoff of S.C.R.A.T.C.H. (School and Community Resources to Avoid and Take Control of Head Lice), a campaign to educate school nurses, students, parents and the general public about the prevention and control of head lice. NASN has teamed up with Sciele Pharma, Inc., a Shionogi company, on the multi-faceted program, which is being launched as children throughout the U.S. head...

2009-08-05 10:00:00

Sciele Pharma, Inc., a Shionogi Company, today announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is available now by prescription nationwide in time for peak head lice season as children will shortly be headed back to school. Each year, approximately 6 to 12 million children...

2008-11-07 09:00:05

Sciele Pharma, Inc.: -- Statistically and clinically significant increase in all three co-primary endpoints -- Well tolerated and devoid of systemic side effects Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora"-AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced that the European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature...

2008-10-23 09:00:10

Sciele Pharma, Inc., a Shionogi Company, today announced that Addrenex Pharmaceuticals, Inc. has initiated its Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic receptor agonist, specific to Alpha-2 receptors. Larry Dillaha, Chief Medical Officer of Sciele Pharma, said, "We are pleased...

2008-10-09 18:00:12

On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the completion of Shionogi's acquisition of Sciele for US$31.00 per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the indirect wholly owned subsidiary of Shionogi with and into Sciele. Sciele is now an indirect wholly owned subsidiary of Shionogi. As a result of the merger, effective as of 5:00 p.m. Eastern...

2008-10-09 09:00:10

On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the successful completion of the cash tender offer by Shionogi's indirect wholly owned subsidiary, Tall Bridge, Inc. ("Purchaser"), to acquire all outstanding shares of common stock of Sciele for $31.00 per share. The subsequent offering period for the tender offer expired at 5:00 p.m., New York City time, on Wednesday, October 8, 2008. The depositary for the tender offer has...

2008-10-06 06:00:36

On October 6, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the successful completion of the tender offer by Shionogi's indirect wholly owned subsidiary, Tall Bridge, Inc. ("Purchaser"), to acquire all outstanding shares of common stock of Sciele for $31.00 per share. The initial offering period expired, as scheduled, at 12:00 midnight, New York City time, on Friday, October 3, 2008. The depositary for the tender offer has advised...

2008-09-30 15:00:17

Sciele Pharma, Inc. ("Sciele") (NASDAQ:SCRX), a specialty pharmaceutical company, today announced that Plethora Solutions Holdings PLC ("Plethora") (AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, has completed its European Phase III study of PSD502 for the treatment of premature ejaculation (PE) in Europe. The study was initiated in December 2007 and these results from the blinded study are expected in the fourth quarter of 2008....

2008-09-19 06:00:29

Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced today that the waiting period under the Hart Scott Rodino Antitrust Improvements Act of 1976 with respect to Shionogi's indirect wholly owned subsidiary's cash tender offer for all outstanding shares of common stock of Sciele at a price of $31.00 per share expired at 11:59 P.M., New York City time, on September 18, 2008. Accordingly, the condition to the tender offer with respect to the...

2008-09-16 09:00:53

Sciele Pharma, Inc. (NASDAQ: SCRX) today announced the completion of a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid. Glycopyrrolate is being studied for use by pediatric patients with chronic, moderate-to-severe drooling as a result of cerebral palsy, mental retardation, or any other neurological condition associated with drooling. The Company completed its open-label, 24-week, multi-center study to assess the safety of oral glycopyrrolate liquid for the...